

Review: Treatments for primary basal cell carcinoma compared

September 18 2018



(HealthDay)—For patients with primary basal cell carcinoma (BCC),

estimated recurrence rates are similarly low for excision, Mohs surgery, curettage and diathermy, and external-beam radiation, according to a review and meta-analysis published online Sept. 18 in the *Annals of Internal Medicine*.

Aaron M. Drucker, M.D., from the Alpert Medical School of Brown University in Providence, R.I., and colleagues conducted a systematic review to examine the [comparative effectiveness](#) and safety of primary BCC treatments in adults. Eighteen interventions in nine categories were compared in 40 randomized trials and five non-randomized studies.

The researchers found that the estimated recurrence rates were similar for excision, Mohs surgery, curettage and diathermy, and external-beam radiation (3.8, 3.8, 6.9, and 3.5 percent, respectively). For cryotherapy, curettage and cryotherapy, 5-fluorouracil, imiquimod, and photodynamic therapy using methyl-aminolevulinic acid or aminolevulinic acid, the recurrence rates were higher (22.3, 19.9, 18.8, 14.1, 18.8, and 16.6 percent, respectively). Compared with excision or cryotherapy, for phototherapy using methyl-aminolevulinic acid or [aminolevulinic acid](#) there was a higher proportion of patients reporting good or better cosmetic outcomes (93.8 and 95.8, respectively, versus 77.8 and 51.1 percent, respectively).

"Surgical treatments and external-beam radiation have low recurrence rates for the [treatment](#) of low-risk BCC, but substantial uncertainty exists about their comparative effectiveness versus other treatments," the authors write. "Gaps remain regarding high-risk BCC subtypes and important outcomes, including costs."

More information: [Abstract/Full Text](#)
[Editorial \(subscription or payment may be required\)](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: Review: Treatments for primary basal cell carcinoma compared (2018, September 18)
retrieved 8 May 2024 from

<https://medicalxpress.com/news/2018-09-treatments-primary-basal-cell-carcinoma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.